Photo taken from Sabine Brookman-May/LinkedIn
Feb 21, 2024, 18:28
Sabine Brookman-May: TAR-200 was safe and well tolerated, with encouraging preliminary efficacy in IR
Sabine Brookman-May, Professor of Urology at the Ludwig-Maximilians University of Munchen, posted on X/Twitter:
“Finally out: results of the legacy phase 1b study which built the groundwork for our ongoing phase 2 + 3 studies with the intravesical gemcitabine releasing system TAR-200.
TAR-200 was safe and well tolerated, with encouraging preliminary efficacy in IR.”
Source: Sabine Brookman-May/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12